4D Molecular Therapeutics, Inc. (FDMT) - Dilution Analysis

S-3 filing: 4D Molecular Therapeutics, Inc. files an S-3 registration statement to offer and sell up to $400 million in the aggregate of common stock, preferred stock, debt securities, warrants and units from time to time in one or more offerings.

10-Q filing | 52.3M shares outstanding

8-K filing: 4D Molecular Therapeutics, Inc. exchanged shares of common stock for pre-funded warrants with RA Capital and BVF. RA Capital exchanged 4,850,000 shares, and BVF exchanged 1,750,000 shares.

10-Q filing | 56.1M shares outstanding

10-Q filing | 46.7M shares outstanding

10-Q filing | 46.3M shares outstanding

POS AM filing: 4D Molecular Therapeutics, Inc. may offer and sell up to $250,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings for general corporate purposes.

10-K filing | 46.3M shares outstanding

8-K filing: 4D Molecular Therapeutics, Inc. entered into an exchange agreement with RA Capital Healthcare Fund, L.P., exchanging 535,000 shares of the Company's common stock for a pre-funded warrant to acquire 535,000 shares of the Company's common stock.

10-Q filing | 46.2M shares outstanding

10-Q filing | 55.3M shares outstanding

10-Q filing | 49.3M shares outstanding

10-K filing | 49.8M shares outstanding

10-Q filing | 42.3M shares outstanding

10-Q filing | 38.3M shares outstanding

S-3 filing: 4D Molecular Therapeutics, Inc. may offer and sell up to $300.0 million in the aggregate of common stock, preferred stock, debt securities, warrants and units from time to time in one or more offerings.

10-Q filing | 32.7M shares outstanding

10-K filing | 32.4M shares outstanding

10-Q filing | 32.4M shares outstanding

S-3 filing: This S-3 filing relates to the proposed resale of up to 2,837,914 shares of 4D Molecular Therapeutics, Inc. common stock by selling stockholders.

10-Q filing | 32.3M shares outstanding

10-Q filing | 32.3M shares outstanding

S-3 filing: 4D Molecular Therapeutics, Inc. is filing an S-3 to offer and sell up to $300,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings.

10-K filing | 32.2M shares outstanding

10-Q filing | 32.1M shares outstanding

10-Q filing | 27.0M shares outstanding

10-Q filing | 26.7M shares outstanding

10-K filing | 26.7M shares outstanding

S-1/A filing: This S-1/A filing includes information on recent sales of unregistered securities, director and executive officer compensation, and indemnification agreements.

S-1/A filing: This is an S-1/A filing for 4D Molecular Therapeutics, Inc. and includes information on recent sales of unregistered securities, including Series B and C redeemable convertible preferred stock, common stock warrants, and stock options and awards issued under the 2015 Equity Incentive Plan.

S-1 filing: This S-1 filing includes information about a Series C convertible preferred stock financing where 4,200,353 shares were issued at $18.00 per share for approximately $75.6 million, and an offering of common stock by the company.

RW filing: 4D Molecular Therapeutics, Inc. requests the withdrawal of its Registration Statement on Form S-1 (File No. 333-234021) because it is no longer pursuing an initial public offering of its common stock at this time.